HighPoint Blog

Thomas Hasmann, VP Market Access

Thomas brings a wealth of experience from industry in various roles in the areas of Market Access, Patient Access, and Marketing. In addition, Thomas has a diverse commercial background across a broad range of therapeutic areas ranging from primary care to rare diseases. Thomas has a degree in Pharmacy and holds a PhD in Pharmacology from the University in Heidelberg, Germany.

Recent Posts

Market Access is becoming more and more challenging. This is irrespective of drug classes and new technologies. Payers are applying the same scrutiny on orphan drugs as on drugs for primary care. This is driven by increased budget constraints in healthcare systems and the heterogeneity of reimbursement systems worldwide.

Read More

Market access functions in life sciences are always evolving. Disrupted by the increasing share of Biosimilars, companies are reorganizing themselves. In this environment, market access departments are absolutely required and given increased responsibilities — all driven by external and internal factors.

Read More

Biosimilars are on the agenda of several players in the pharmaceutical industry. Several companies’ new leg of growth seems to be the creation of a biosimilar franchise. The question is “How real are the opportunities in an ever growing competitive environment?"

In the next 5 years, Biosimilars could hit the market to compete with some key biologics cumulating sales of more than EUR40 billion....

Read More